TAKE Limited
TAKE Limited (TAKE) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Healthcare Services›Healthcare Research, Analytics & Technology
takelimited.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 Cr | 18 Cr | 17 Cr | 13 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 54 Cr | 30 Cr |
| Operating expenses (approx.) | 19 Cr | 16 Cr | 16 Cr | 28 Cr | 2 Cr | 1 Cr | 3 Cr | 0.77 Cr | 0.29 Cr | 0.35 Cr | 55 Cr | 31 Cr |
| EBITDA | -1 Cr | 2 Cr | 1 Cr | -15 Cr | -2 Cr | -1 Cr | -3 Cr | -0.77 Cr | -0.29 Cr | -0.35 Cr | -0.82 Cr | -0.26 Cr |
| OPM % | -6.8% | 10.0% | 6.7% | -115.2% | — | — | — | — | — | — | -1.5% | -0.9% |
| Other income | 0.28 Cr | 0.14 Cr | 1 Cr | 0.07 Cr | 0 Cr | 0 Cr | 9 Cr | 0.04 Cr | 0 Cr | 1 Cr | 5 Cr | 1 Cr |
| Interest | 2 Cr | 1 Cr | 1 Cr | 1 Cr | 0.49 Cr | 0.50 Cr | 0.73 Cr | 0.17 Cr | 0.17 Cr | 0.0009 Cr | 0 Cr | 0.0007 Cr |
| Depreciation | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0.0020 Cr | 0.0020 Cr | 0.0020 Cr | 0.0020 Cr | 0.0002 Cr |
| Profit before tax | -5 Cr | -2 Cr | -0.95 Cr | -111 Cr | -4 Cr | -2 Cr | 48 Cr | -0.91 Cr | 6 Cr | 1 Cr | 4 Cr | 1 Cr |
| Tax % | -5.1% | 3.8% | -123.9% | 0.1% | -1.6% | 3.4% | 0.0% | 0.0% | 2.5% | 0.0% | 0.0% | 0.0% |
| Net profit | -5 Cr | -2 Cr | -2 Cr | -111 Cr | -4 Cr | -2 Cr | 48 Cr | -0.91 Cr | 6 Cr | 1 Cr | 4 Cr | 1 Cr |
| EPS (₹) | ₹-0.36 | ₹-0.11 | ₹-0.15 | ₹-7.56 | ₹-0.26 | ₹-0.11 | ₹3.26 | ₹-0.06 | ₹0.43 | ₹0.07 | ₹0.29 | ₹0.07 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,213 Cr | 774 Cr | 655 Cr | 189 Cr | 66 Cr | 0 Cr | 54 Cr | Sign in for TTM |
| Operating expenses (approx.) | 2,044 Cr | 847 Cr | 648 Cr | 208 Cr | 79 Cr | 7 Cr | 56 Cr | Sign in for TTM |
| EBITDA | 169 Cr | -73 Cr | 7 Cr | -19 Cr | -13 Cr | -7 Cr | -2 Cr | Sign in for TTM |
| OPM % | 7.6% | -9.4% | 1.1% | -10.1% | -20.5% | — | -3.5% | Sign in for TTM |
| Other income | 26 Cr | 12 Cr | 17 Cr | 8 Cr | 2 Cr | 10 Cr | 7 Cr | Sign in for TTM |
| Interest | 41 Cr | 37 Cr | 29 Cr | 7 Cr | 5 Cr | 2 Cr | 0.35 Cr | Sign in for TTM |
| Depreciation | 167 Cr | 115 Cr | 80 Cr | 17 Cr | 8 Cr | 0.04 Cr | 0.0081 Cr | Sign in for TTM |
| Profit before tax | -13 Cr | -436 Cr | -771 Cr | -99 Cr | -118 Cr | 37 Cr | 11 Cr | Sign in for TTM |
| Tax % | 15.3% | -3.1% | -0.5% | -1.7% | -1.0% | 0.0% | 1.5% | Sign in for TTM |
| Net profit | -11 Cr | -450 Cr | -782 Cr | -100 Cr | -120 Cr | 37 Cr | 11 Cr | Sign in for TTM |
| EPS (₹) | ₹-0.85 | ₹-30.91 | ₹-53.50 | ₹-6.86 | ₹-8.18 | ₹2.56 | ₹0.74 | Sign in for TTM |
| Dividend payout % | — | — | — | — | — | 0.1% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr |
| Reserves | 0 Cr | 0 Cr | 0 Cr | 94 Cr | -23 Cr | 6 Cr | 16 Cr |
| Borrowings | — | — | — | 33 Cr | 28 Cr | — | — |
| Other liabilities | — | — | — | 83 Cr | 69 Cr | 16 Cr | 5 Cr |
| Total liabilities | — | — | — | 224 Cr | 88 Cr | 36 Cr | 36 Cr |
| Fixed assets (net) | — | — | — | 8 Cr | 22 Cr | 0 Cr | 0 Cr |
| CWIP | — | — | — | 10 Cr | — | 0 Cr | — |
| Investments | — | — | — | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | — | — | — | 0.78 Cr | 0.80 Cr | 0 Cr | 0 Cr |
| Trade receivables | — | — | — | 30 Cr | 7 Cr | 0 Cr | 0.22 Cr |
| Cash & bank | — | — | — | 11 Cr | 0.84 Cr | 3 Cr | 0.26 Cr |
| Other assets | — | — | — | 164 Cr | 58 Cr | 33 Cr | 36 Cr |
| Total assets | — | — | — | 224 Cr | 88 Cr | 36 Cr | 36 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 30 Cr | 20 Cr | 9 Cr | -16 Cr | -4 Cr |
| Cash from investing | — | — | -31 Cr | -2 Cr | -7 Cr | 22 Cr | 2 Cr |
| Cash from financing | — | — | -55 Cr | -36 Cr | -12 Cr | -3 Cr | -0.72 Cr |
| Net cash flow | — | — | -55 Cr | -18 Cr | -10 Cr | 3 Cr | -3 Cr |
| Free cash flow (OCF − Capex) | — | — | -2 Cr | 12 Cr | 1 Cr | -16 Cr | -4 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | — | — | -64.3% | -111.9% | 191.9% | 36.6% |
| ROE % | — | — | — | -92.3% | — | 182.5% | 35.0% |
| Debtor days | — | — | — | 58 | 39 | — | 1 |
| Inventory days | — | — | — | 3 | 12 | — | 0 |
| Days payable | — | — | — | 104 | 260 | — | 9 |
| Cash conversion cycle | — | — | — | -42 | -209 | — | -7 |
| Debt / equity | — | — | — | 0.31 | — | — | — |
| Current ratio | — | — | — | 0.89 | 0.40 | 1.48 | 4.54 |
| Net debt / EBITDA | 0.00 | — | 0.00 | — | — | — | — |
Compare with peers
Loading peers…